Advisor Partners’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | $541K | Buy |
2,653
+833
| +46% | +$170K | 0.04% | 458 |
|
|
2022
Q1 | $383K | Sell |
1,820
-1,645
| -47% | -$358K | 0.02% | 601 |
|
|
2021
Q4 | $832K | Sell |
3,465
-673
| -16% | -$173K | 0.05% | 362 |
|
|
2021
Q3 | $1.17M | Sell |
4,138
-368
| -8% | -$121K | 0.08% | 240 |
|
|
2021
Q2 | $1.56M | Sell |
4,506
-74
| -2% | -$22.4K | 0.1% | 191 |
|
|
2021
Q1 | $1.28M | Sell |
4,580
-367
| -7% | -$99K | 0.09% | 217 |
|
|
2020
Q4 | $1.21M | Sell |
4,947
-2,402
| -33% | -$620K | 0.09% | 203 |
|
|
2020
Q3 | $2.08M | Sell |
7,349
-30
| -0.4% | -$8.37K | 0.18% | 108 |
|
|
2020
Q2 | $1.97M | Sell |
7,379
-1,586
| -18% | -$477K | 0.18% | 111 |
|
|
2020
Q1 | $2.84M | Buy |
8,965
+2,323
| +35% | +$705K | 0.34% | 58 |
|
|
2019
Q4 | $1.95M | Buy |
6,642
+474
| +8% | +$132K | 0.2% | 114 |
|
|
2019
Q3 | $1.44M | Buy |
6,168
+1,066
| +21% | +$248K | 0.17% | 126 |
|
|
2019
Q2 | $1.19M | Buy |
5,102
+480
| +10% | +$111K | 0.15% | 137 |
|
|
2019
Q1 | $1.09M | Sell |
4,622
-1,654
| -26% | -$521K | 0.14% | 148 |
|
|
2018
Q4 | $1.89M | Buy |
6,276
+671
| +12% | +$214K | 0.3% | 71 |
|
|
2018
Q3 | $1.98M | Buy |
5,605
+195
| +4% | +$67.1K | 0.27% | 71 |
|
|
2018
Q2 | $1.57M | Buy |
5,410
+871
| +19% | +$245K | 0.27% | 80 |
|
|
2018
Q1 | $1.24M | Sell |
4,539
-769
| -14% | -$239K | 0.23% | 96 |
|
|
2017
Q4 | $1.82M | Buy |
5,308
+531
| +11% | +$170K | 0.32% | 66 |
|
|
2017
Q3 | $1.5M | Buy |
4,777
+266
| +6% | +$78.8K | 0.29% | 69 |
|
|
2017
Q2 | $1.22M | Buy |
4,511
+324
| +8% | +$85.7K | 0.29% | 90 |
|
|
2017
Q1 | $1.15M | Buy |
4,187
+195
| +5% | +$55.1K | 0.31% | 82 |
|
|
2016
Q4 | $1.13M | Sell |
3,992
-290
| -7% | -$86K | 0.34% | 73 |
|
|
2016
Q3 | $1.34M | Buy |
4,282
+1,471
| +52% | +$436K | 0.45% | 53 |
|
|
2016
Q2 | $680K | Sell |
2,811
-701
| -20% | -$185K | 0.24% | 108 |
|
|
2016
Q1 | $914K | Sell |
3,512
-487
| -12% | -$129K | 0.34% | 83 |
|
|
2015
Q4 | $1.23M | Buy |
3,999
+15
| +0.4% | +$4.31K | 0.42% | 67 |
|
|
2015
Q3 | $1.16M | Sell |
3,984
-950
| -19% | -$314K | 0.49% | 54 |
|
|
2015
Q2 | $2.06M | Buy |
4,934
+387
| +9% | +$155K | 0.79% | 30 |
|
|
2015
Q1 | $1.92M | Sell |
4,547
-99
| -2% | -$39K | 0.82% | 26 |
|
|
2014
Q4 | $1.56M | Buy |
4,646
+44
| +1% | +$14.2K | 0.69% | 36 |
|
|
2014
Q3 | $1.52M | Sell |
4,602
-37
| -0.8% | -$12.2K | 0.87% | 31 |
|
|
2014
Q2 | $1.46M | Buy |
4,639
+220
| +5% | +$66.2K | 0.72% | 36 |
|
|
2014
Q1 | $1.35M | Buy |
4,419
+151
| +4% | +$47.9K | 0.74% | 34 |
|
|
2013
Q4 | $1.19M | Buy |
4,268
+165
| +4% | +$42.7K | 0.69% | 38 |
|
|
2013
Q3 | $988K | Buy |
4,103
+327
| +9% | +$73.2K | 0.71% | 40 |
|
|
2013
Q2 | $813K | Buy |
+3,776
| New | +$807K | 0.67% | 40 |
|
Other funds holding BIIB
Advisor Partners's BIIB Position: Q2 2022 in Review
Advisor Partners increased its Biogen (BIIB) stake by 46% in Q2 2022, buying an estimated $170K and bringing the position to 2,653 shares worth $541K. The position accounts for 0.04% of the portfolio, ranked #458.
Advisor Partners first reported a position in BIIB in Q2 2013 and has held it in 37 quarters since. The position peaked at $2.84M in Q1 2020. 928 funds tracked by Wall St. Rank hold BIIB as of Q2 2022.
- Advisor Partners held 2,653 shares of Biogen worth $541K as of Q2 2022.
- Advisor Partners bought 833 Biogen shares in Q2 2022, an estimated $170K.
- Biogen made up 0.04% of Advisor Partners's portfolio in Q2 2022, its #458 holding.
- Advisor Partners first reported a position in Biogen in Q2 2013 and has held it in 37 quarters since.
- Advisor Partners's Biogen position peaked at $2.84M in Q1 2020.
- 928 funds tracked by Wall St. Rank held Biogen as of Q2 2022.
Based on Advisor Partners's 13F filing for Q2 2022, filed 11 Aug 2022.